> Detailanzeige

Vázquez-Ucha, Juan Carlos; Seoane-Estévez, Alejandro; Rodiño-Janeiro, Bruno Kotska; González-Bardanca, Mónica; Conde-Pérez, Kelly; Martínez-Guitián, Marta; Alvarez-Fraga, Laura; Arca-Suárez, Jorge; Lasarte-Monterrubio, Cristina; Gut, Marta; Gut, Ivo; Álvarez-Tejado, Miguel; Oviaño, Marina; Beceiro, Alejandro; Bou, Germán; Merino, Irene; Cercenado, Emilia; Gómez, Rosa; Soler, Tamara; Gracia-Ahufinger, Irene; Martín, Lina; Galán, Fátima; Tormo, Nuria; Carlos Rodríguez, Juan; [...]

Activity of imipenem/relebactam against a Spanish nationwide collection of carbapenemase-producing Enterobacterales

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Activity of imipenem/relebactam against a Spanish nationwide collection of carbapenemase-producing Enterobacterales
  • Beteiligte: Vázquez-Ucha, Juan Carlos; Seoane-Estévez, Alejandro; Rodiño-Janeiro, Bruno Kotska; González-Bardanca, Mónica; Conde-Pérez, Kelly; Martínez-Guitián, Marta; Alvarez-Fraga, Laura; Arca-Suárez, Jorge; Lasarte-Monterrubio, Cristina; Gut, Marta; Gut, Ivo; Álvarez-Tejado, Miguel; Oviaño, Marina; Beceiro, Alejandro; Bou, Germán; Merino, Irene; Cercenado, Emilia; Gómez, Rosa; Soler, Tamara; Gracia-Ahufinger, Irene; Martín, Lina; Galán, Fátima; Tormo, Nuria; Carlos Rodríguez, Juan; [...]
  • Erschienen: Oxford University Press (OUP), 2021
  • Erschienen in: Journal of Antimicrobial Chemotherapy
  • Sprache: Englisch
  • DOI: 10.1093/jac/dkab043
  • ISSN: 0305-7453; 1460-2091
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background</jats:title> <jats:p>Imipenem/relebactam is a novel carbapenem/β-lactamase inhibitor combination, developed to act against carbapenemase-producing Enterobacterales (CPE).</jats:p> </jats:sec> <jats:sec> <jats:title>Objectives</jats:title> <jats:p>To assess the in vitro activity of imipenem/relebactam against a Spanish nationwide collection of CPE by testing the susceptibility of these isolates to 16 widely used antimicrobials and to determine the underlying β-lactam resistance mechanisms involved and the molecular epidemiology of carbapenemases in Spain.</jats:p> </jats:sec> <jats:sec> <jats:title>Materials and methods</jats:title> <jats:p>Clinical CPE isolates (n = 401) collected for 2 months from 24 hospitals in Spain were tested. MIC50, MIC90 and susceptibility/resistance rates were interpreted in accordance with the EUCAST guidelines. β-Lactam resistance mechanisms and molecular epidemiology were characterized by WGS.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>For all isolates, high rates of susceptibility to colistin (86.5%; MIC50/90 = 0.12/8 mg/L), imipenem/relebactam (85.8%; MIC50/90 = 0.5/4 mg/L) and ceftazidime/avibactam (83.8%, MIC50/90 = 1/≥256 mg/L) were observed. The subgroups of isolates producing OXA-48-like (n = 305, 75.1%) and KPC-like enzymes (n = 44, 10.8%) were highly susceptible to ceftazidime/avibactam (97.7%, MIC50/90 = 1/2 mg/L) and imipenem/relebactam (100.0%, MIC50/90 = ≤0.25/1 mg/L), respectively.</jats:p> <jats:p>The most widely disseminated high-risk clones of carbapenemase-producing Klebsiella pneumoniae across Spain were found to be ST11, ST147, ST392 and ST15 (mostly associated with OXA-48) and ST258/512 (in all cases producing KPC).</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions</jats:title> <jats:p>Imipenem/relebactam, colistin and ceftazidime/avibactam were the most active antimicrobials against all CPEs. Imipenem/relebactam is a valuable addition to the antimicrobial arsenal used in the fight against CPE, particularly against KPC-producing isolates, which in all cases were susceptible to this combination.</jats:p> </jats:sec>
  • Zugangsstatus: Freier Zugang